Table 1.
Characteristics | Total (n = 29) |
HIV D+/R+ (n = 19) | HIV D−/R+ (n = 10)a | P Value |
---|---|---|---|---|
Age, y, median (IQR) | 58 (57–64) | 57 (56–64) | 58 (57–62) | .82 |
Male sex | 24 (83) | 16 (84) | 8 (80) | .78 |
Race | ||||
White | 17 (59) | 11 (58) | 6 (60) | .86 |
African American | 8 (28) | 5 (26) | 3 (30) | |
Asian | 1 (3) | 1 (5) | 0 (0) | |
American Indian or Alaska Native | 1 (3) | 1 (5) | 0 (0) | |
Not specified | 2 (7) | 1 (5) | 1 (10) | |
Latino ethnicity | 6 (21) | 4 (21) | 2 (20) | |
Duration of HIV infection, y, median (IQR) | 28 (15–32) | 30 (15–33) | 26 (9–29) | .16 |
CD4+ T-cell count, median (IQR) | 278 (198–393) | 290 (198–427) | 273 (145–392) | .71 |
HIV RNA < 200 copies/mL | 29 (100) | 19 (100) | 10 (100) | |
Received SLK | 5 (17) | 5 (26) | 0 (0) | .07 |
ART regimenb,c | ||||
INSTI containing | 24 (83) | 16 (84) | 8 (80) | .78 |
NRTI containing | 11 (38) | 8 (42) | 3 (30) | .52 |
NNRTI containing | 5 (17) | 4 (21) | 1 (10) | .45 |
PI containing | 1 (3) | 0 (0) | 1 (10) | .16 |
Immunosuppressionb | ||||
Induction regimen | ||||
Corticosteroids only | 25 (86) | 15 (79) | 10 (100) | .29 |
Basiliximab and corticosteroids | 3 (10) | 3 (16) | 0 (0) | |
Basiliximab only | 1 (3) | 1 (5) | 0 (0) | |
Maintenancec | ||||
Tacrolimus | 27 (93) | 17 (89) | 10 (100) | .29 |
Mycophenolate mofetil (MMF) | 22 (76) | 14 (74) | 8 (80) | .71 |
Prednisone | 23 (79) | 13 (68) | 10 (100) | .05 |
Everolimus | 1 (3) | 1 (5) | 0 (0) | .46 |
Donor characteristics | ||||
CD4+ T-cell count, median (IQR)d | … | 156 (112–272) | ND | |
On ART | … | 11 (58) | NA | |
HIV load <200 copies/mLe | … | 10 (53) | NA | |
Not on ART | … | 8 (42) | NA | |
HIV load, copies/mL, median (IQR) | … | 15 186 (760–290 222) | NA |
Data are presented as median (IQR) for continuous measures, and No. (%) for categorical/binary measures. P values were calculated by Wilcoxon rank sum test while Pearson χ2 test was used for categorical and binary variables.
Abbreviations: ART, antiretroviral therapy; D, donor; HIV, human immunodeficiency virus; INSTI, integrase strand transfer inhibitor; IQR, interquartile range; ND, not done; NA, not applicable; NNRTI, nonnucleoside reverse transcriptase inhibitors; PI, protease inhibitor; R, recipient; RNA, ribonucleic acid; SLK, simultaneous liver-kidney transplant.
Of 10 D−/R+, 3 donors had a false-positive HIV test.
Immunosuppression and ART regimens were reported as active prescriptions at 4 weeks posttransplant.
Percentages may add up to more than 100 because an individual can fall under more than 1 category.
Of 19 D+/R−, 2 donors had missing information on CD4+ T-cell count.
Of 19 D+/R−, 1 donor had missing information on HIV load.